Negev Capital
Overview
Negev Capital is a psychedelic medical intervention investment fund with assets of USD$30+ million. The Company invests in drug discovery, with a focus on preclinical and/or Phase 1 stages of developm…
Investment Focus
- Companies developing psychedelic medical interventions for neuropsychiatric disorders
- Strong management teams
- Robust intellectual property
- Commitment to responsible and therapeutic use of psychedelic medications
Portfolio Companies
Reach Negev Capital directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Negev Capital
What sectors does Negev Capital invest in?
Negev Capital invests in Healthcare, Pharmaceuticals, Biotechnology, Mental Health, Drug Discovery and Psychedelic Medicine, and is based in United States. Negev Capital is listed as a venture capital in the ConnectSafely investor database.
What stage does Negev Capital invest at?
Negev Capital backs companies at Pre-Seed, Seed, Early Stage, Series A, Series B and Growth.
Which regions does Negev Capital invest in?
Negev Capital invests across United States, United Kingdom, Mexico, Israel and Cayman Islands.
Who are the partners at Negev Capital?
Team members listed for Negev Capital include Gennady Drushlyak (Chief Financial Officer) and Stuart Seidman (Partner).
What companies has Negev Capital invested in?
Negev Capital's portfolio includes Filament Health and Clairvoyant Therapeutics.
How do I contact Negev Capital?
Negev Capital's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
